Acquisition
Video: Valeant buys rights to Visudyne Add to ...
Valeant Pharmaceuticals has purchased the rights to Visudyne, an eye drug, from Vancouver-based QLT Inc.
Watch More Video:
-
Macy's rings up $6.39-billion sales
Retail sales unexpectedly rise
Briton jailed for bomb detector scam
Stressed consumers are paying more - but not getting more
-
McDonald's: Slow times for fast food
Long winter cools H&M sales
Daily Digit: U.S. retail sales slip again
Lukewarm retail sales blamed on weather chill
-
Car prices on the rise as auto industry picks up speed
B.C. makes history by eliminating HST
How long can S&P home-building stocks outpace index average?
After dead pig scandal, worries about safety of China's pork
-
Easier credit bringing car buyers back
How to attract and then hold onto good salespeople
How to sell in a brave new digital world
BNN's upgrades and downgrades
-
Tumblr fills void in Yahoo's offerings: analyst
Leadership lessons from Manchester United
Should Greece go back to the drachma?
Ryanair's high-flying results
| Security | Price | Change | |
|---|---|---|---|
| QLT-T QLT Inc. | 8.1 | Add to watchlist | |
| VRX-T Valeant Pharmaceuticals Intl. | 80.42 | Add to watchlist |
